
Please try another search
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Name | Age | Since | Title |
---|---|---|---|
Andrew Blauvelt | - | - | Chairman of Scientific Advisory Board |
Peter Evan Harwin | 39 | 2024 | Independent Director |
Samarth Kulkarni | 47 | 2024 | Independent Chairman of Board |
Kristine M. Ball | 53 | 2024 | Independent Director |
Carl Linden Dambkowski | 40 | 2024 | Independent Director |
Cameron Turtle | 35 | 2024 | Independent Director |
Lawrence Otto Klein | 42 | 2024 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review